プラスミドDNA製造の市場規模、シェア、動向分析レポート：疾患別、グレード別、用途別、市場開拓段階別、地域別、セグメント予測、2024年～2030年

プラスミドDNA製造市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のプラスミドDNA製造市場規模は、2024年から2030年にかけて21.01%のCAGRで拡大し、2030年には67億米ドルに達する見込みです。

慢性疾患の有病率の上昇に加え、ヘルスケア産業におけるプラスミドDNAの応用範囲の広さが、業界の成長を促進すると予想されています。プラスミドDNAは、ワクチン抗原の生産や遺伝子治療などの治療用途に直接使用することができます。さらに、遺伝子クローニングや遺伝子マッピングなど、さまざまな研究目的にも利用できます。遺伝子治療を選択する患者数の増加は、今後数年間の業界の成長を促進すると予想されます。

clinicaltrials.govによると、世界のパイプラインプログラム（第I相試験から第III相試験）全体の細胞＆遺伝子治療の数は、2018年の289から2022年には327に増加しました。さらに、米国FDAは、製品製造に関するいくつかの政策を通じて、先端治療分野の技術革新を常に支援しています。細胞・遺伝子治療製品の増加に伴い、業界ではプラスミドDNAを大規模に製造する必要性が高まると思われます。COVID-19パンデミックは業界の成長にプラスの影響を与えると予想されます。例えば、2021年9月、インドは最初のCOVID-19 DNAワクチンを承認しました。これはMission COVID Surakshaの一環としてDBT-BIRACと提携して製造された世界初のCOVID-19 DNAワクチンです。

円形DNAは、COVID-19感染を予防するインドのZyCoV-Dワクチン接種に使用されています。さらに、世界の業界の主要企業は、市場での存在感を高めるために様々な戦略的取り組みを行っており、これも成長を促進すると予想されます。例えば、2022年6月、バイオシナはCDMOサービスの提供に新たな専用GMPスイートでのプラスミドDNA生産の拡大を発表しました。このスイートは、最大300Lのシングルユース発酵容量と適切なスケールの下流処理機械を備えています。

プラスミドDNA製造市場レポートハイライト

• GMPグレードタイプは2023年に最大の収益シェアを占めました。GMPグレードのプラスミドDNAは、生体内分布や毒性試験を含む遺伝子治療やワクチン接種の前臨床試験で広く利用されています。
• 遺伝子ワクチン接種における臨床研究用途のプラスミドDNAの重要性が高まっているため、2023年には臨床治療分野が世界の業界を支配しました。
• 細胞・遺伝子治療応用分野は、遺伝性疾患や遺伝性障害の治療に遺伝子治療の需要が高いことから、2023年に業界をリードしました。
• 北米は、ヘルスケアインフラの改善、可処分所得の高さ、先端療法の研究開発に従事するセンターや研究機関の数の多さ、同地域における先端療法の採用の増加などにより、2023年の地域別市場で優位を占めました。
• アジア太平洋は、この分野における研究開発活動の活発化と主要企業の存在により、予測期間中に最も速いCAGRを記録すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場動向と展望
• 市場力学
  • 遺伝子治療を選択する患者数の増加
  • 遺伝子治療のための堅牢なパイプライン
  • 競争の激しい市場と市場関係者によるさまざまな戦略
  • さまざまな医療療法におけるプラスミドDNAの需要の増加
• 市場抑制要因分析
  • 遺伝子治療に関連する規制、科学、倫理的課題
• 事業環境分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • COVID-19感染症の影響分析

第4章 グレードビジネス分析

• 世界のプラスミドDNA製造市場：グレード変動分析
• 研究開発グレード
  • 研究開発グレード市場、2018年～2030年
• GMPグレード
  • GMPグレード市場、2018年～2030年

第5章 開発段階のビジネス分析

• 世界のプラスミドDNA製造市場：開発段階の変動分析
• 前臨床療法
• 臨床治療学
• 市販の治療薬

第6章 アプリケーションビジネス分析

• 世界のプラスミドDNA製造市場：用途変動分析
• DNAワクチン
  • DNAワクチン市場、2018年～2030年
• 細胞および遺伝子治療
  • 細胞および遺伝子治療市場、2018年～2030年
• 免疫療法
  • 免疫療法市場、2018年～2030年
• その他
  • その他市場、2018年～2030年

第7章 疾病ビジネス分析

• 世界のプラスミドDNA製造市場：疾病変動分析
• 感染症
• がん
• 遺伝性疾患
• その他

第8章 地域ビジネス分析

• 地域別の世界のプラスミドDNA製造市場シェア、2022年および2030年
• 北米
  • 北米プラスミドDNA製造市場、2018年～2030年
  • 米国
  • カナダ
• 欧州
  • 欧州のプラスミドDNA製造市場、2018年～2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋のプラスミドDNA製造市場、2018年～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカのプラスミドDNA製造市場、2018年～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカのプラスミドDNA製造市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 企業の分類
• 戦略マッピング
• Company Market/Position Share Analysis, 2022年
• 企業プロファイル・一覧表
  • Charles River Laboratories
  • Danaher
  • VGXI, Inc.
  • Kaneka Corp.
  • Lonza
  • Nature Technology
  • Cell and Gene Therapy Catapult
  • Eurofins Genomics
  • Luminous BioSciences, LLC
  • Akron Biotech

List of Tables

• Table 1 List Of Secondary Sources
• Table 2 List Of Abbreviations
• Table 3 Global Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 4 Global Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 5 Global Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 6 Global Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 7 North America Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 8 North America Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 9 North America Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 10 North America Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 11 North America Plasmid DNA Manufacturing Market by Country, 2018 - 2030 (USD Million)
• Table 12 U.S. Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 13 U.S. Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 14 U.S. Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 15 U.S. Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 16 Canada Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 17 Canada Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 18 Canada Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 19 Canada Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 20 Europe Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 21 Europe Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 22 Europe Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 23 Europe Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 24 Europe Plasmid DNA Manufacturing Market by Country, 2018 - 2030 (USD Million)
• Table 25 UK Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 26 UK Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 27 UK Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 28 UK Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 29 Germany Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 30 Germany Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 31 Germany Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 32 Germany Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 33 France Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 34 France Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 35 France Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 36 France Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 37 Italy Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 38 Italy Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 39 Italy Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 40 Italy Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 41 Spain Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 42 Spain Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 43 Spain Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 44 Spain Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 45 Denmark Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 46 Denmark Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 47 Denmark Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 48 Denmark Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 49 Sweden Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 50 Sweden Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 51 Sweden Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 52 Sweden Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 53 Norway Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 54 Norway Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 55 Norway Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 56 Norway Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific Plasmid DNA Manufacturing Market by Country, 2018 - 2030 (USD Million)
• Table 62 China Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 63 China Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 64 China Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 65 China Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 66 Japan Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 67 Japan Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 68 Japan Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 69 Japan Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 70 India Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 71 India Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 72 India Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 73 India Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 74 South Korea Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 75 South Korea Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 76 South Korea Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 77 South Korea Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 78 Australia Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 79 Australia Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 80 Australia Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 81 Australia Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 82 Thailand Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 83 Thailand Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 84 Thailand Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 85 Thailand Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 86 Latin America Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 87 Latin America Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 88 Latin America Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 89 Latin America Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 90 Latin America Plasmid DNA Manufacturing Market by Country, 2018 - 2030 (USD Million)
• Table 91 Brazil Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 92 Brazil Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 93 Brazil Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 94 Brazil Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 95 Mexico Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 96 Mexico Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 97 Mexico Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 98 Mexico Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 99 Argentina Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 100 Argentina Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 101 Argentina Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 102 Argentina Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 103 Middle East & Africa Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Plasmid DNA Manufacturing Market by Country, 2018 - 2030 (USD Million)
• Table 108 South Africa Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 109 South Africa Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 110 South Africa Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 111 South Africa Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 116 UAE Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 117 UAE Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 118 UAE Plasmid DNA Manufacturing Market by Application, 2018 - 2030 (USD Million)
• Table 119 UAE Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 120 Kuwait Plasmid DNA Manufacturing Market by Grade, 2018 - 2030 (USD Million)
• Table 121 Kuwait Plasmid DNA Manufacturing Market by Development Phase, 2018 - 2030 (USD Million)
• Table 122 Kuwait Plasmid DNA Manufacturing Market By Application, 2018 - 2030 (USD Million)
• Table 123 Kuwait Plasmid DNA Manufacturing Market by Disease, 2018 - 2030 (USD Million)
• Table 124 Participant's Overview
• Table 125 Financial Performance
• Table 126 Key Companies Undergoing Expansions
• Table 127 Key Companies Undergoing Acquisitions
• Table 128 Key Companies Undergoing Collaborations
• Table 129 Key Companies Launching New Products/Services
• Table 130 Key Companies Undergoing Partnerships
• Table 131 Key Companies Undertaking Other Strategies

List of Figures

• Figure 1. Market Others process
• Figure 2. Data triangulation techniques
• Figure 3. Primary Others pattern
• Figure 4. Market Others approaches
• Figure 5. Value-chain-based sizing & forecasting
• Figure 6. QFD modeling for market share assessment
• Figure 7. Market formulation & validation
• Figure 8. Market summary, 2023 (USD Million)
• Figure 9. Market segmentation & scope
• Figure 10. Market driver impact
• Figure 11. Market restraint impact
• Figure 12. Penetration & growth prospect mapping
• Figure 13. Porter's analysis
• Figure 14. SWOT analysis
• Figure 15. Global plasmid DNA manufacturing market: Grade outlook and key takeaways
• Figure 16. Global plasmid DNA manufacturing market: Grade movement analysis
• Figure 17. Global R&D grade market, 2018 - 2030 (USD Million)
• Figure 18. Global GMP grade market, 2018 - 2030 (USD Million)
• Figure 19. Global plasmid DNA manufacturing market: Development phase outlook and key takeaways
• Figure 20. Global plasmid DNA manufacturing market: Development phase movement analysis
• Figure 21. Global pre-clinical therapeutics market, 2018 - 2030 (USD Million)
• Figure 22. Global clinical therapeutics market, 2018 - 2030 (USD Million)
• Figure 23. Global marketed therapeutics market, 2018 - 2030 (USD Million)
• Figure 24. Global plasmid DNA manufacturing market: Application outlook and key takeaways
• Figure 25. Global plasmid DNA manufacturing market: Application movement analysis
• Figure 26. Global DNA vaccines market, 2018 - 2030 (USD Million)
• Figure 27. Global cell & gene therapy market, 2018 - 2030 (USD Million)
• Figure 28. Global immunotherapy market, 2018 - 2030 (USD Million)
• Figure 29. Global others market, 2018 - 2030 (USD Million)
• Figure 30. Global plasmid DNA manufacturing market: Disease outlook and key takeaways
• Figure 31. Global plasmid DNA manufacturing market: Disease movement analysis
• Figure 32. Global infectious disease market, 2018 - 2030 (USD Million)
• Figure 33. Global cancer market, 2018 - 2030 (USD Million)
• Figure 34. Global genetic disorder market, 2018 - 2030 (USD Million)
• Figure 35. Global Others market, 2018 - 2030 (USD Million)
• Figure 36. Global plasmid DNA manufacturing market: Regional outlook and key takeaways
• Figure 37. North America plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
• Figure 38. U.S. key country dynamics
• Figure 39. U.S. plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
• Figure 40. Canada key country dynamics
• Figure 41. Canada plasmid DNA manufacturing market, 2018 - 2030 (USD Million)
• Figure 42. Europe plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 43. Germany key country dynamics
• Figure 44. Germany plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 45. France key country dynamics
• Figure 46. France plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 47. UK key country dynamics
• Figure 48. UK plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 49. Italy key country dynamics
• Figure 50. Italy plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 51. Spain key country dynamics
• Figure 52. Spain plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 53. Denmark key country dynamics
• Figure 54. Denmark plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 55. Sweden key country dynamics
• Figure 56. Sweden plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 57. Norway key country dynamics
• Figure 58. Norway plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 59. Asia-Pacific plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 60. China key country dynamics
• Figure 61. China plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 62. India key country dynamics
• Figure 63. India plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 64. South Korea key country dynamics
• Figure 65. South Korea plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 66. Japan key country dynamics
• Figure 67. Japan plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 68. Australia key country dynamics
• Figure 69. Australia plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 70. Thailand key country dynamics
• Figure 71. Thailand plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 72. Latin America plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 73. Brazil key country dynamics
• Figure 74. Brazil plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 75. Mexico key country dynamics
• Figure 76. Mexico plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 77. Argentina key country dynamics
• Figure 78. Argentina plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 79. MEA plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 80. South Africa key country dynamics
• Figure 81. South Africa plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 82. Saudi Arabia key country dynamics
• Figure 83. Saudi Arabia plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 84. UAE key country dynamics
• Figure 85. UAE plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 86. Kuwait key country dynamics
• Figure 87. Kuwait plasmid DNA manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Figure 88. Market participant categorization
• Figure 89. Plasmid DNA manufacturing market share analysis, 2023
• Figure 90. Strategy framework

Plasmid DNA Manufacturing Market Growth & Trends:

The global plasmid DNA manufacturing market size is expected to reach USD 6.70 billion by 2030, expanding at a CAGR of 21.01% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases, combined with the wide application scope of plasmid DNA in the healthcare industry is expected to drive the industry growth. Plasmid DNA can be used directly for therapeutic applications, such as the production of vaccine antigens or gene therapy. Moreover, it can be utilized for various research purposes, such as gene cloning, gene mapping, etc. The rising number of patients choosing gene therapy is expected to drive industry growth in the coming years.

According to clinicaltrials.gov, the number of cell & gene therapies across global pipeline programs (Phase I to Phase III trials) increased from 289 in 2018 to 327 in 2022. Furthermore, the U.S. FDA provides constant support for innovations in the advanced therapy arena via several policies concerning product manufacturing. With increased cell and gene therapy products, the industry will see an increased need for manufacturing plasmid DNA on a larger scale. The COVID-19 pandemic is anticipated to positively impact industry growth. For instance, in September 2021, India approved the first COVID-19 DNA vaccine. It is the world's first COVID-19 DNA vaccine manufactured in partnership with DBT-BIRAC as part of Mission COVID Suraksha.

Circular DNA is used in India's ZyCoV-D vaccination to protect against COVID-19 infection. Furthermore, key entities in the global industry are undertaking various strategic initiatives to strengthen their market presence, which is also expected to propel growth. For instance, in June 2022, BioCina announced the expansion of the production of plasmid DNA in a new dedicated GMP suite to its offering of CDMO services. The suite has a single-use fermentation capacity of up to 300 L and appropriately scaled downstream processing machinery.

Plasmid DNA Manufacturing Market Report Highlights:

• The GMP grade type segment held the largest revenue share in 2023. GMP-grade plasmid DNAs are broadly utilized in pre-clinical trials in gene therapy or vaccination including biodistribution and toxicology studies
• The clinical therapeutics segment dominated the global industry in 2023 owing to the increased importance of plasmid DNA for clinical research applications in genetic vaccination
• The cell & gene therapy application segment led the industry in 2023 owing to the high demand for gene therapy for the treatment of several inherited diseases and genetic disorders
• North America was the dominant regional market in 2023 due to improved healthcare infrastructure, high disposable income, presence of a substantial number of centers and institutes that are engaged in R&D of advanced therapies, and increased adoption of advanced therapies in the region
• Asia Pacific is anticipated to register the fastest CAGR during the forecast years on account of the increasing R&D activities in this field and the presence of key players

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Information analysis
  • 1.2.2. Market formulation & data visualization
  • 1.2.3. Data validation & publishing
• 1.3. Information Procurement
  • 1.3.1. Primary Others
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Market Model
• 1.7. Objectives
  • 1.7.1. Objective 1
  • 1.7.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Increasing number of patients opting for gene therapy
  • 3.3.2. Robust pipeline for gene therapies
  • 3.3.3. Highly competitive market and various strategies undertaken by market players
  • 3.3.4. Increasing demand for plasmid DNA in various medical therapies
• 3.4. Market Restraint Analysis
  • 3.4.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Grade Business Analysis

• 4.1. Global Plasmid DNA Manufacturing Market: Grade Movement Analysis
• 4.2. R&D Grade
  • 4.2.1. R&D Grade Market, 2018 - 2030 (USD Million)
• 4.3. GMP Grade
  • 4.3.1. GMP Grade Market, 2018 - 2030 (USD Million)

Chapter 5. Development Phase Business Analysis

• 5.1. Global Plasmid DNA Manufacturing Market: Development Phase Movement Analysis
• 5.2. Pre-Clinical Therapeutics
  • 5.2.1. Pre-Clinical Therapeutics Market, 2018 - 2030 (USD Million)
• 5.3. Clinical Therapeutics
  • 5.3.1. Clinical Therapeutics Market, 2018 - 2030 (USD Million)
• 5.4. Marketed Therapeutics
  • 5.4.1. Marketed Therapeutics Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Global Plasmid DNA Manufacturing Market: Application Movement Analysis
• 6.2. DNA Vaccines
  • 6.2.1. DNA Vaccines Market, 2018 - 2030 (USD Million)
• 6.3. Cell & Gene Therapy
  • 6.3.1. Cell & Gene Therapy Market, 2018 - 2030 (USD Million)
• 6.4. Immunotherapy
  • 6.4.1. Immunotherapy Market, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Disease Business Analysis

• 7.1. Global Plasmid DNA Manufacturing Market: Disease Movement Analysis
• 7.2. Infectious Disease
  • 7.2.1. Infectious Disease Market, 2018 - 2030 (USD Million)
• 7.3. Cancer
  • 7.3.1. Cancer Market, 2018 - 2030 (USD Million)
• 7.4. Genetic Disorder
  • 7.4.1. Genetic Disorder Market, 2018 - 2030 (USD Million)
• 7.5. Others
  • 7.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Global Plasmid DNA Manufacturing Market Share By Region, 2022 & 2030
• 8.2. North America
  • 8.2.1. North America Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Target Disease Prevalence
    • 8.2.2.5. U.S. Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Target Disease Prevalence
    • 8.2.3.5. Canada Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.2. Germany
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. Germany Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. UK Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. France Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Target Disease Prevalence
    • 8.3.5.5. Italy Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Target Disease Prevalence
    • 8.3.6.5. Spain Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Target Disease Prevalence
    • 8.3.7.5. Denmark Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Target Disease Prevalence
    • 8.3.8.5. Sweden Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Target Disease Prevalence
    • 8.3.9.5. Norway Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Japan Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. China Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Target Disease Prevalence
    • 8.4.4.5. India Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Target Disease Prevalence
    • 8.4.5.5. South Korea Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Target Disease Prevalence
    • 8.4.6.5. Australia Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Target Disease Prevalence
    • 8.4.7.5. Thailand Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. Brazil Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Mexico Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Target Disease Prevalence
    • 8.5.4.5. Argentina Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Target Disease Prevalence
    • 8.6.2.5. South Africa Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Target Disease Prevalence
    • 8.6.3.5. Saudi Arabia Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Target Disease Prevalence
    • 8.6.4.5. UAE Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Target Disease Prevalence
    • 8.6.5.5. Kuwait Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market/Position Share Analysis, 2022
• 9.4. Company Profiles/Listing
  • 9.4.1. Charles River Laboratories
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Danaher
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. VGXI, Inc.
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Kaneka Corp.
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Lonza
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Nature Technology
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Cell and Gene Therapy Catapult
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Eurofins Genomics
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Luminous BioSciences, LLC
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Akron Biotech
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives